Table 1. Distribution of person-day data by sex, student group, initial vaccination series completion date, initial vaccine type, and week in the study period.
| # unboosted person-days | # unboosted PCR-positive cases | Incidence rate per 100 person-days (unboosted) | # boosted person-days | # boosted PCR-positive cases | Incidence rate per 100 person days (boosted) | Total # person-days | Total # PCR-positive cases | Incidence rate per 100 person days (total) | |
|---|---|---|---|---|---|---|---|---|---|
| n (col %) | n (col %) | n (col %) | n (col %) | n (col %) | n (col %) | ||||
| Sex | |||||||||
| Female | 72,195 (53%) | 908 (50%) | 1.3 | 12,034 (61%) | 75 (59%) | 0.6 | 84,229 (54%) | 983 (51%) | 1.2 |
| Male | 63,019 (47%) | 891 (50%) | 1.4 | 7,808 (39%) | 52 (41%) | 0.7 | 70,827 (46%) | 943 (49%) | 1.3 |
| Student group a | |||||||||
| UG-frat/sor | 21,333 (16%) | 517 (29%) | 2.4 | 2,986 (15%) | 35 (28%) | 1.2 | 24,319 (16%) | 552 (29%) | 2.3 |
| UG-athlete | 7,629 (6%) | 170 (9%) | 2.2 | 781 (4%) | 7 (6%) | 0.9 | 8,410 (5%) | 177 (9%) | 2.1 |
| UG-other | 89,860 (66%) | 985 (55%) | 1.1 | 11,446 (58%) | 65 (51%) | 0.6 | 101,306 (65%) | 1,050 (55%) | 1.0 |
| LA | 6,166 (5%) | 30 (2%) | 0.5 | 1,734 (9%) | 3 (2%) | 0.2 | 7,900 (5%) | 33 (2%) | 0.4 |
| GM | 4,979 (4%) | 84 (5%) | 1.7 | 1,061 (5%) | 15 (12%) | 1.4 | 6,040 (4%) | 99 (5%) | 1.6 |
| VM | 5,247 (4%) | 13 (1%) | 0.2 | 1,834 (9%) | 2 (2%) | 0.1 | 7,081 (5%) | 15 (1%) | 0.2 |
| Month of initial vaccine series completion b | |||||||||
| January 2021 | 278 (0%) | 5 (0%) | 1.8 | 158 (1%) | 1 (1%) | 0.6 | 436 (0%) | 6 (0%) | 1.4 |
| February 2021 | 1,926 (1%) | 27 (2%) | 1.4 | 1,185 (6%) | 8 (6%) | 0.7 | 3,111 (2%) | 35 (2%) | 1.1 |
| March 2021 | 9,623 (7%) | 184 (10%) | 1.9 | 3,801 (19%) | 34 (27%) | 0.9 | 13,424 (9%) | 218 (11%) | 1.6 |
| April 2021 | 41,897 (31%) | 667 (37%) | 1.6 | 9,006 (45%) | 60 (47%) | 0.7 | 50,903 (33%) | 727 (38%) | 1.4 |
| May 2021 | 54,169 (40%) | 646 (36%) | 1.2 | 3,653 (18%) | 21 (17%) | 0.6 | 57,822 (37%) | 667 (35%) | 1.2 |
| June 2021 | 10,883 (8%) | 113 (6%) | 1.0 | 1,095 (6%) | 2 (2%) | 0.2 | 11,978 (8%) | 115 (6%) | 1.0 |
| July 2021 | 7,958 (6%) | 77 (4%) | 1.0 | 582 (3%) | 0 (0%) | 0.0 | 8,540 (6%) | 77 (4%) | 0.9 |
| August 2021 | 5,301 (4%) | 55 (3%) | 1.0 | 160 (1%) | 0 (0%) | 0.0 | 5,461 (4%) | 55 (3%) | 1.0 |
| September 2021 | 2,774 (2%) | 21 (1%) | 0.8 | 106 (1%) | 0 (0%) | 0.0 | 2,880 (2%) | 21 (1%) | 0.7 |
| October 2021 | 392 (0%) | 4 (0%) | 1.0 | 72 (0%) | 1 (1%) | 1.4 | 464 (0%) | 5 (0%) | 1.1 |
| November 2021 | 13 (0%) | 0 (0%) | 0.0 | 24 (0%) | 0 (0%) | 0.0 | 37 (0%) | 0 (0%) | 0.0 |
| Initial vaccine series type | |||||||||
| BNT162b2 | 83,826 (62%) | 1,179 (66%) | 1.4 | 12,532 (63%) | 83 (65%) | 0.7 | 96,358 (62%) | 1,262 (66%) | 1.3 |
| mRNA-1273 | 38,480 (28%) | 481 (27%) | 1.3 | 3,297 (17%) | 24 (19%) | 0.7 | 41,777 (27%) | 505 (26%) | 1.2 |
| Ad26.COV2.S | 6,234 (5%) | 101 (6%) | 1.6 | 1,186 (6%) | 11 (9%) | 0.9 | 7,420 (5%) | 112 (6%) | 1.5 |
| Other WHO-approved vaccines | 6,674 (5%) | 38 (2%) | 0.6 | 2,827 (14%) | 9 (7%) | 0.3 | 9,501 (6%) | 47 (2%) | 0.5 |
| Week in the study period | |||||||||
| Week 0 | 89,480 (66%) | 520 (29%) | 0.6 | 11,256 (57%) | 46 (36%) | 0.4 | 100,736 (65%) | 566 (29%) | 0.6 |
| Week 1 | 39,642 (29%) | 1,211 (67%) | 3.1 | 6,263 (32%) | 68 (54%) | 1.1 | 45,905 (30%) | 1,279 (66%) | 2.8 |
| Week 2 | 4,614 (3%) | 47 (3%) | 1.0 | 1,524 (8%) | 8 (6%) | 0.5 | 6,138 (4%) | 55 (3%) | 0.9 |
| Week 3 | 1,478 (1%) | 21 (1%) | 1.4 | 799 (4%) | 5 (4%) | 0.6 | 2,277 (1%) | 26 (1%) | 1.1 |
| Total | 135,214 (100%) | 1,799 (100%) | 1.3 | 19,842 (100%) | 127 (100%) | 0.6 | 155,056 (100%) | 1,926 (100%) | 1.2 |
aDescriptions for student group categories. UG-frat/sor: Undergraduate students affiliated with fraternities/sororities; UG-athlete: Undergraduate varsity athletes that have no affiliation with fraternities/sororities; UG-other: Other undergraduate students; LA: Professional students in the law school; GM: Postbaccalaureate professional students in the business school; VM: Professional students in the college of veterinary medicine.
bInitial vaccination series completion is the date of receiving 1 dose of Ad26.COV2.S or 2 doses of other WHO-approved vaccines.